logo

For the Inventor, By the Inventor

New York, NY, United States of America

Kadmon Corporation, LLC


USPTO Granted Patents = 23

% Expired Patents = 4.3



Trademarks = 3

Forward Citations = 24

Loading Chart...
Loading Chart...

29 inventors (with patents filed for the assignee):

goldMedal Masha V Poyurovsky (11 out of 12 patents)

silverMedal Kevin G Liu (11 out of 17 patents)

bronzeMedal Ji-In Kim (10 out of 15 patents)

4.  Dan Lu (7 out of 11 patents)

5.  Zhenping Zhu (7 out of 11 patents)

6.  Alexandra Zanin-Zhorov (4 out of 5 patents)

7.  Kellen L Olszewski (4 out of 5 patents)

8.  Anthony Michael Barsotti (3 out of 5 patents)

9.  Koi Morris (3 out of 12 patents)

10.  Eduardas Skucas (3 out of 3 patents)

11.  Rigen Mo (3 out of 3 patents)

12.  Xuemei Yu (2 out of 2 patents)

13.  Samuel D Waksal (2 out of 4 patents)

14.  Zhanna Polonskaya (2 out of 2 patents)

15.  Jingya Zhang (2 out of 2 patents)


23 patents:

1. 12741959 - Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease (2026-09-22),
2. 12636362 - Human Anti-VEGFR-2/KDR Antibodies (2026-05-26),
3. 12097202 - Methods of administering Belumosudil for treatment of chronic graft versus host disease (2024-09-24),
4. 12030857 - Glucose uptake inhibitors (2024-07-09),
5. 11952369 - Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease (2024-04-09),
6. 11926596 - Inhibitors of Rho associated coiled-coil containing protein kinase (2024-03-12),
7. 11633475 - Human anti-VEGFR-2/KDR antibodies (2023-04-25),
8. 11613531 - Inhibitors of RHO associated coiled-coil containing protein kinase (2023-03-28),
9. 11479533 - Inhibitors of Rho associated coiled-coil containing protein kinase (2022-10-25),
10. 11311541 - Treatment of GVHD (2022-04-26),
11. 11071735 - Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors (2021-07-27),
12. 10988484 - Glucose uptake inhibitors (2021-04-27),
13. 10729691 - Treatment of infectious diseases with glucose uptake inhibitors (2020-08-04),
14. 10696660 - Rho kinase inhibitors (2020-06-30),
15. 10588968 - Human anti-VEGFR-2/KDR antibodies (2020-03-17),
Kadmon Corporation, LLC is a biopharmaceutical company based in New York, specializing in the development of innovative therapies for unmet medical needs. The organization focuses on advancing treatments in areas such as immunology and oncology, leveraging its expertise in molecular biology and drug development. Kadmon is dedicated to improving patient outcomes through its research initiatives and commitment to scientific excellence, aiming to bring transformative therapies to market for patients worldwide.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Kadmon Corporation, LLC
23 Patents

#367 in New York, NY

#865 in New York

#14,415 in US

#27,649 in the World

New York, NY (US)
New York, NY, United States of America

Kadmon Corporation, LLC

Forward Citations = 24

29 inventors:

goldMedal Masha V Poyurovsky (11 out of 12 patents)

silverMedal Kevin G Liu (11 out of 17 patents)

bronzeMedal Ji-In Kim (10 out of 15 patents)

4.  Dan Lu (7 out of 11 patents)

5.  Zhenping Zhu (7 out of 11 patents)

Please report any incorrect information to [email protected]
Loading…